Rare frequencey of point mutations for codon 12, 13 and 61 of ras gene in italian neuroblastoma.

Int J Oncol

GASLINI INST,GENOA,ITALY. UNIV PADUA,DEPT PEDIAT,I-35100 PADUA,ITALY. UNIV MODENA,INST PATHOL,I-41100 MODENA,ITALY. UNIV BOLOGNA,DEPT EXPTL PATHOL,I-40126 BOLOGNA,ITALY.

Published: September 1993

Single point mutations of ras oncogenes are found in many tumors and contribute to the pathogenesis of the cancer. The product of the ras gene, p21 protein, was found expressed in several neuroblastoma tissues. However, the role of ras gene in this tumor has yet to be clarified. To contribute to the understanding of the ras activation, 79 fresh biopsies of neuroblastoma were studied to investigate the possibility that ras would be activated by point mutation. Analysis of H-ras and N-ras was performed by means of PCR and SSO, while K-ras mutations were detected by multiplex-ASPCR. None of the neuroblastomas examined showed H- or K-ras activation, while N-ras mutations were demonstrated in only three patients (3,7%). N-myc oncogene is amplified in a substantial number of patients with neuroblastoma. N-myc amplification was studied by Southern blot technique. N-myc amplification was demonstrated in 13.2% of patients less than 1 year of age at diagnosis and 23% of older children. Two of the patients (one stage I and one stage IVs) with N-ras mutation and without N-myc amplification had a good outcome, while the third (stage IVs) with N-myc amplification had a poor prognosis. These results suggest that ras activation is a rare event in both amplified and non-amplified neuroblastoma tumors and that N-ras activation was not involved in the clinical outcome of these patients. Moreover, our data suggest that p21 expression is induced by a post-transcriptional activation.

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.3.3.529DOI Listing

Publication Analysis

Top Keywords

n-myc amplification
16
ras gene
12
point mutations
8
ras activation
8
stage ivs
8
ras
7
neuroblastoma
5
activation
5
patients
5
n-myc
5

Similar Publications

Neuroblastoma is the most common extra-cranial solid tumour in children. Over half of all high-risk cases are expected to succumb to the disease even after chemotherapy, surgery, and immunotherapy. Although the importance of MYCN amplification in this disease is indisputable, the mechanistic details remain enigmatic.

View Article and Find Full Text PDF

Neuroblastoma is the most common extracranial solid tumor in children, and a leading cause of childhood cancer deaths. All neuroblastomas arise from neural crest-derived sympathetic neuronal progenitors, but numerous mutations, the most common of which is MYCN amplification, give rise to these lesions. Epigenetic aberrations also play a role in oncogenesis and tumor progression.

View Article and Find Full Text PDF

MYCN-amplified RB1 wild-type (MYCNRB1) retinoblastoma is a rare and aggressive subtype, often resistant to standard therapies. Identifying unique MRI features is crucial for diagnosing this subtype, as biopsy is not recommended. This study aimed to differentiate MYCNRB1 from the most prevalent RB1 retinoblastoma using pretreatment MRI and radiomics.

View Article and Find Full Text PDF

Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status.

BMC Cancer

October 2024

Department of Pediatric Oncology, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, West Huan-Hu Rd, Ti Yuan Bei, Hexi District, 300060, Tianjin, Tianjin, China.

Article Synopsis
  • Neuroblastoma shows significant genetic diversity, impacting patient immune status and prognosis, prompting a study of 31 patients with varying genetic traits.
  • Testing revealed that 22 patients had genetic alterations, particularly MYCN amplification and chromosome deletions, which correlated with worse event-free survival (EFS) rates.
  • An increase in regulatory T cells and cytokines like interleukin-10 (IL-10) was observed, indicating an immunosuppressive environment that further worsens EFS, especially among patients with high IL-10 levels.
View Article and Find Full Text PDF
Article Synopsis
  • - MYCN amplification is linked to poor outcomes in childhood neuroblastoma and the study investigates the signaling dependencies associated with it through genetic manipulation in mice.
  • - A mutation in the RNF121 gene was found to result in decreased tumor formation, with RNF121 playing a crucial role in enhancing MYCN protein stability and contributing to tumor growth.
  • - Elevated RNF121 levels correlate with poor prognosis in neuroblastoma and laryngeal cancer, suggesting it as a potential target for new cancer therapies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!